Chart of the Day: The Trump Plan for Prescription Drugs

After griping for hours about President Trump’s upcoming speech on reducing prescription drug prices, you’d think I’d at least listen to the damn thing and then comment on it, wouldn’t you? I guess so. That would be the fair thing to do.

But here’s the thing: Sometimes I get tired of being sucked into long, dry analyses of Republican plans that we all know perfectly well are meaningless. Someone has to do it, and very often that someone is me. It’s my role in the vast politico-industrial complex, after all. But seriously, who cares? Trump himself barely understood what he was reading, and whatever it was, Congress is going to ignore it. Plus it’s Friday, and I’m tired. So fuck it.

Besides, there’s really no need for all that work. There are hundreds of analysts out there who know more than me about this stuff, and they render instant decisions on it via the stock market. So if all you want to know is whether Trump’s plan is good for consumers or good for pharmaceutical companies, just check out how pharmaceutical stocks did as Trump was delivering his speech. If stocks went down, that’s good news for consumers. If stocks went up, it’s good news for drug companies.

Can you guess which way pharmaceutical stocks went? Huh? Can you?

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you'll agree is worth supporting.

payment methods

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you’ll agree is worth supporting.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate